Pretreatment Fibrinogen-Albumin Ratio (FAR) Associated with Treatment Response and Survival in Advanced Non-Small Cell Lung Cancer Patients Treated with First-Line Anti-PD-1 Therapy Plus Platinum-Based Combination Chemotherapy

PURPOSE: PD-1 inhibitors have been routinely used to treat advanced non-small cell lung cancer (NSCLC) and have significantly improved clinical outcomes. In this study, we aimed to explore the influence of pretreatment fibrinogen-albumin ratio (FAR) on treatment response and survival in advanced NSC...

Descripción completa

Detalles Bibliográficos
Autores principales: Yuan, Chengliang, Huang, Meifang, Wang, Huilin, Jiang, Wei, Su, Cuiyun, Zhou, Shaozhang
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Dove 2022
Materias:
Original Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8801367/
https://www.ncbi.nlm.nih.gov/pubmed/35115834
http://dx.doi.org/10.2147/CMAR.S347547

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8801367/
https://www.ncbi.nlm.nih.gov/pubmed/35115834
http://dx.doi.org/10.2147/CMAR.S347547

Ejemplares similares